Roberta Escalera
Endocrinology, Diabetes & Metabolism · Mesa, AZNPI 1225672785
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations.
Across 254 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$789
- Novo Nordisk$391
- Bayer$337
- Abbott$336
- Dexcom, Inc.$321
- AbbVie$320
- plus $3K from 41 others
What the payments were for
- Food & beverage$5,356100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,370 in reported general payments places this provider in the 65th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $193,469 |
| MounjaroTirzepatide | 41 | $78,817 |
| TrulicityDulaglutide | 42 | $63,741 |
| JardianceEmpagliflozin | 39 | $54,107 |
| TymlosAbaloparatide | 12 | $31,516 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $30,404 |
| HumalogInsulin Lispro | 14 | $6,112 |
| SynthroidLevothyroxine Sodium | 56 | $5,657 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $4,724 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 32 | $4,648 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $2,735 |
| Levothyroxine Sodium | 159 | $2,240 |
| Metformin Hcl | 56 | $558 |
| Liothyronine Sodium | 16 | $489 |
| Metformin Hcl ErMetformin Hcl | 26 | $269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $391 | $193,469131 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $789 | $148,67097 claims |
| Boehringer IngelheimJardiance | $117 | $54,10739 claims |
| Radius Health, Inc.Tymlos | $180 | $31,51612 claims |
| AbbVieSynthroid | $320 | $5,65756 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $59 | $2,240159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Mesa
- Vidhyalakshmi KannanMesa$111K
- Gyan BrardMesa$12K
- Shahzad ShadmanyMesa$9K
- Muhammad SethiTucson$670K
- Kevin YuenPhoenix$404K
- Amir HarariScottsdale$361K
- Joan BaileyPhoenix$316K
- Kristina BlohmScottsdale$220K
- Karen HerbstTucson$200K
- Laura KnechtCave Creek$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.